Cameron Diaz on Menopause: What the Disclosure Laws Actually Mean for You

Why Cameron Diaz and Menopause Are Showing Up in Your Search Results

Cameron Diaz has not been invisible about aging. In her 2016 book The Longevity Book, she examined what science knows about the female body across decades, and she has since spoken in interviews about entering menopause and rethinking what midlife health looks like for women. That is worth acknowledging: a major cultural figure normalizing a conversation that medicine has historically dismissed.

But here is the problem. When celebrities describe their personal menopause "protocols," millions of women take notes. Some of those protocols involve specific hormones, supplements, peptides, or lifestyle regimens. Some involve paid partnerships with brands. And most viewers have no idea which disclosures are legally required, which ones are missing, and how to separate a clinically valid recommendation from a sponsored post dressed up as personal wisdom.

This article answers three specific questions. What does U.S. Law actually require when a public figure promotes a health treatment? What does good menopause care genuinely look like, according to current clinical guidelines? And how do you evaluate what you see on social media against what your own body actually needs?

The Legal Framework: What Disclosure Laws Require

Disclosure law in this area is largely governed by the Federal Trade Commission. The FTC updated its Endorsement Guides in 2023, and those rules apply directly to celebrity health content.

The Material Connection Rule

Under 16 CFR Part 255, any "material connection" between an endorser and a brand must be clearly and conspicuously disclosed. A material connection includes payment, free products, stock ownership, a family relationship, or any other benefit that might affect how a viewer weighs the endorsement. The 2023 revision explicitly extended these requirements to social media posts, podcasts, and online video content.

"Clearly and conspicuously" means the disclosure must be hard to miss. A small hashtag buried in a caption does not meet the standard. A verbal disclosure buried at the end of a 10-minute video does not meet the standard. The FTC has stated in guidance that disclosures placed where consumers are unlikely to notice them are legally insufficient.

What the 2023 Updates Changed

The 2023 revised Guides added several provisions directly relevant to health content. Endorsers who make objective health claims must have a reasonable basis for those claims. They cannot simply describe their personal experience and imply it will generalize. For health products specifically, the FTC notes that individual results are often not typical and that disclosures must reflect that.

Brands, not just influencers, bear liability. A company that facilitates an undisclosed endorsement can be fined alongside the individual promoter. This matters because many celebrity-brand partnerships in the menopause supplement and telehealth space are structured as equity arrangements or long-term consulting deals that may not be disclosed on a post-by-post basis.

Celebrity Speech vs. Medical Advice: The Legal Line

Saying "I feel better since I started this protocol" is personal testimony. Saying "this hormone dose will reduce your hot flashes" is a medical claim. The line between them matters legally because medical claims require substantiation, and health claims in advertising are subject to FTC and FDA oversight. The FDA regulates health claims on dietary supplements under 21 CFR Part 101 and requires that structure/function claims not imply disease treatment.

When a celebrity describes a specific hormone regimen, dose, or branded peptide as the reason she feels good, and that content is sponsored, the law requires both disclosure of the sponsorship and a reasonable scientific basis for the claim. Most viewers do not know to ask whether either of those requirements has been met.

What Good Menopause Care Actually Looks Like

Celebrity menopause content often focuses on a single dramatic intervention: a specific hormone pellet, a proprietary supplement stack, or a fasting protocol. Clinical guidelines tell a different story.

The Menopause Society Position

The Menopause Society (formerly NAMS) 2023 Position Statement on Hormone Therapy is the most authoritative U.S. Guideline on this topic. It states that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for most healthy women under age 60 or within 10 years of menopause onset. The position statement explicitly emphasizes individualized decision-making based on a woman's symptom burden, cardiovascular risk, bone health, personal and family history of breast cancer, and her own values.

No protocol is universally correct. A 49-year-old in perimenopause with intact uterus has different medical needs than a 57-year-old who is 6 years post-menopause with premature ovarian insufficiency diagnosed at 38. These distinctions rarely appear in celebrity content.

Vasomotor Symptoms: Prevalence and Treatment

Approximately 75% of women experience hot flashes during the menopause transition, and for about 25% of those women, symptoms are severe enough to interfere with sleep, work, and quality of life. Hot flashes can begin 2 to 8 years before the final menstrual period, during the perimenopause window, and persist for a median of 7.4 years in some populations, according to the SWAN study published in JAMA Internal Medicine.

FDA-approved options for vasomotor symptoms include systemic estrogen (with progestogen if the uterus is present), the low-dose paroxetine salt Brisdelle (7.5 mg), and fezolinetant (Veozah), a neurokinin B receptor antagonist approved in May 2023. Non-hormonal options also include venlafaxine 75 mg and gabapentin 300 mg nightly, both used off-label with reasonable evidence.

Bone Health: A Menopause-Specific Risk

Estrogen deficiency accelerates bone loss. Women lose an average of 1 to 2% of bone mass per year in the first decade after menopause, a rate roughly twice that of men the same age. The ACOG Practice Bulletin on Osteoporosis Prevention recommends dual-energy X-ray absorptiometry (DEXA) screening beginning at age 65 for average-risk women, earlier for women with early menopause or other risk factors.

Hormone therapy does reduce fracture risk. The Women's Health Initiative showed a 34% reduction in hip fracture risk with conjugated equine estrogen plus medroxyprogesterone acetate over 5.6 years, though the absolute risk reduction was small. Calcium and vitamin D intake targets (1,200 mg calcium daily and 800 to 1,000 IU vitamin D daily for women over 50) remain important foundations regardless of whether hormone therapy is used.

Sex-Specific Physiology: Why Menopause Is Not the Same for Every Woman

Most menopause content, celebrity or otherwise, treats the transition as a single event with a single set of solutions. The reality is a spectrum shaped by genetics, reproductive history, metabolic status, and life stage. Here is a framework that clinical care actually uses.

Perimenopause (Typically Ages 45 to 52)

Hormonal chaos defines perimenopause. Estrogen does not decline smoothly; it fluctuates wildly, sometimes spiking above premenopausal levels before dropping. Progesterone declines more steadily as ovulation becomes irregular. This means a woman in perimenopause may have normal or even elevated estrogen on a blood test taken on the wrong day, yet still be symptomatic.

FSH is not a reliable single-test diagnosis in perimenopause. ACOG recommends that FSH levels be interpreted in clinical context rather than used as a binary cutoff. Diagnosis is clinical: 12 months of amenorrhea defines menopause, but symptoms and cycle irregularity define perimenopause.

Contraception matters here. A woman in perimenopause can still conceive. The ACOG guidance on contraception in older women states that contraception should continue until 12 consecutive months without a period. Unintended pregnancy in women over 40 carries higher risks of chromosomal abnormalities, gestational diabetes, and preeclampsia.

Post-Menopause (After 12 Months of Amenorrhea)

Once the final menstrual period is confirmed by 12 months of amenorrhea, estrogen levels remain persistently low. Genitourinary syndrome of menopause (GSM), which includes vaginal dryness, dyspareunia, and recurrent urinary tract infections, affects an estimated 50 to 70% of postmenopausal women but only a minority seek treatment. Topical vaginal estrogen is safe, effective, and not systemically absorbed at meaningful levels, making it an option even for many women with a history of breast cancer, as noted in the 2023 Menopause Society Position Statement.

Premature Ovarian Insufficiency (Before Age 40)

Women who experience ovarian failure before age 40 face a different risk profile entirely. They have a longer duration of estrogen deficiency and face higher rates of osteoporosis, cardiovascular disease, and cognitive changes. The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends hormone therapy until the average age of natural menopause (roughly 51) as a minimum, not as an optional add-on. This population is often invisibilized in celebrity menopause content that implicitly addresses only natural menopause in the fifth decade.

PCOS, Thyroid, and Other Conditions That Change the Menopause Picture

Several conditions disproportionately affecting women interact with the menopause transition in ways that celebrity content rarely addresses.

PCOS in Perimenopause

Women with polycystic ovary syndrome often experience a relative improvement in androgen excess symptoms as estrogen declines, but their metabolic risks (insulin resistance, dyslipidemia, elevated cardiovascular risk) intensify. A 2023 analysis in the Journal of Clinical Endocrinology and Metabolism found that postmenopausal women with a history of PCOS had significantly higher rates of metabolic syndrome than matched controls. Hormone therapy decisions in this group require consideration of androgen levels and metabolic markers, not just symptom relief.

Thyroid Disease

Hypothyroidism affects approximately 10% of women over 50 and produces symptoms that overlap substantially with menopause: fatigue, weight gain, mood changes, and cognitive fog. A woman told she is "just menopausal" deserves a TSH measurement. Postpartum thyroiditis, which may have gone undiagnosed years earlier, can progress to permanent hypothyroidism and emerge symptomatically at perimenopause.

How to Evaluate Celebrity Menopause Content Without Getting Burned

You do not need a law degree or a medical degree to evaluate what you are seeing. A few specific questions cut through most of the noise.

Is there a disclosure? Any content involving a paid partnership, gifted product, equity stake, or consulting arrangement legally requires a clear disclosure. If you do not see one and a product is featured, assume the absence is itself informative.

Is the claim personal experience or a generalized recommendation? "This helped me" is testimony. "This is what you should do" is a medical claim that requires substantiation. These are different things.

Is the person a licensed clinician, and in what state? A celebrity is not a clinician. A clinician featured in celebrity content is practicing under their state license and is subject to professional standards, but their advice is still not a substitute for your personalized care.

What is the evidence base? Many popular menopause supplement ingredients, including ashwagandha, black cohosh, and various botanical blends, have inconsistent evidence. A Cochrane review of black cohosh found insufficient evidence to support its use for menopausal symptoms. That does not mean it is harmful, but it does mean the confidence intervals are wide.

Does the protocol account for your medical history? A woman with a personal history of hormone receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or a history of DVT has contraindications to certain forms of hormone therapy. A generalized celebrity protocol cannot know that.

What Cameron Diaz's Openness Has Actually Contributed

Frankly, public figures who speak openly about menopause do something that clinical medicine has historically failed to do: they make women feel that their symptoms are real and worth treating. Menopause has been systematically under-researched and undertreated for decades. The SWAN study, one of the largest longitudinal studies of menopausal women in the U.S., documented that Black women experience more severe and longer-lasting vasomotor symptoms than white women, yet receive fewer treatment recommendations, a disparity that celebrity content does not typically address but that your clinician should.

Cameron Diaz writing about the female body's aging in The Longevity Book and speaking candidly in interviews about hormonal changes has contributed to reducing the stigma that keeps many women from seeking care. That contribution is real. It is also entirely separable from the clinical and legal questions this article addresses.

The goal is not to dismiss celebrity voices. The goal is to give you a framework for what those voices can and cannot do for your health. They can reduce shame. They can prompt you to ask your clinician questions you might have avoided. They cannot replace the individualized assessment that your specific hormonal history, medical background, and life stage require.

Who This Applies To and Who Needs a Different Approach

Menopause content, including this article, has a range of appropriate audiences. Being specific about that matters.

Good candidates for standard hormone therapy evaluation: Women aged 45 to 60 with bothersome vasomotor symptoms, no personal history of hormone receptor-positive breast cancer, no active liver disease or DVT, and no unexplained vaginal bleeding. This group represents most perimenopausal and early postmenopausal women and is the population for whom the evidence is strongest.

Women who need specialized assessment before any protocol: Women with a history of breast cancer, cardiovascular disease, prior DVT or pulmonary embolism, liver disease, or unexplained bleeding. Women with POI under 40. Women currently pregnant or potentially pregnant. Women with severe depression or who take medications with significant interactions (SSRIs, certain anticonvulsants, some HIV antiretrovirals that affect cytochrome P450 enzymes).

Women who benefit from non-hormonal options specifically: Women who prefer to avoid hormones, women who are not candidates for systemic estrogen, and women whose primary symptoms are mood, sleep disruption, or urogenital rather than hot flashes may do well with fezolinetant, cognitive behavioral therapy for menopause (CBT-M), or low-dose paroxetine, depending on individual presentation.

A Note on Pregnancy and Lactation for Women in Perimenopause

Perimenopause does not reliably prevent pregnancy. Ovulation can occur unpredictably even as cycles become irregular. If you are sexually active and have not completed 12 consecutive months without a period, you are not post-menopausal and pregnancy is biologically possible.

ACOG recommends contraception continue in perimenopausal women until confirmed menopause. Combined hormonal contraceptives are generally avoided in women over 40 who smoke or have cardiovascular risk factors, but progestin-only options, the levonorgestrel IUD, or barrier methods are appropriate. The levonorgestrel IUD has the added benefit of managing heavy perimenopausal bleeding and can be continued with the addition of systemic estrogen for symptom management.

Women who become pregnant in perimenopause face higher rates of pregnancy complications. If you are using hormone therapy in perimenopause and discover you are pregnant, contact your obstetric provider immediately. Systemic estrogen and progesterone used for menopause management are not the same formulations studied in pregnancy support and their safety in confirmed pregnancy is not established in that context.

Regarding lactation: menopause by definition follows the cessation of reproductive cycling, so lactation is not a typical consideration in post-menopausal women. For the rare perimenopausal woman who is breastfeeding a child conceived in late reproductive years, systemic estrogen may reduce milk supply and decisions should be made with a clinician and a lactation consultant together.

How to Talk to Your Clinician After Seeing Celebrity Menopause Content

Bring the content with you. Literally. If you saw a specific protocol described in an interview or on social media, screenshot it or note the source and bring it to your appointment. Ask your clinician to evaluate the specific claims against your personal history.

Useful questions to bring to your appointment:

• "Based on my symptoms and history, am I a candidate for hormone therapy?"
• "What type and route of administration would you recommend for me specifically?"
• "My FSH was tested. What does that result actually mean for my treatment options?"
• "I've been seeing content about [specific supplement or peptide]. Is there evidence for it and does it interact with anything I take?"
• "Do I need any screening before starting treatment, such as a mammogram, lipid panel, or DEXA scan?"

The Menopause Society's certified menopause practitioner directory lists clinicians with specialized training in menopause management. If your current provider is dismissing your symptoms or offering no options beyond "just wait it out," a second opinion from a certified menopause practitioner is a reasonable next step.